Drug Profile


Alternative Names: BVAC-C

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellid Company
  • Class Cancer vaccines; Vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Natural killer cell stimulants; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer

Most Recent Events

  • 24 Jan 2018 Adverse events data from a phase I trial in Cervical cancer released by Cellid
  • 01 Oct 2016 Phase-I clinical trials in Cervical cancer (Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT02866006)
  • 09 Aug 2016 Preclinical trials in Cervical cancer in South Korea (IV) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top